NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia and Genecast Biotechnology Partner to Launch MammaPrint and BluePrint in China
For the first time, early-stage breast cancer patients and their physicians in China can access clinically validated and prospectively proven tests for breast cancer risk of recurrence and molecular subtyping IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS Read More
US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology
Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Read More
An Update on Agendia’s Precision Oncology Achievements in Breast Cancer
As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions Read More
Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations
IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Agendia, Inc., a world leader in precision oncology, today announced the completion of $35 million in financing from investment funds managed by Athyrium Capital Management Read More
An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:
One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question. The Read More
Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients
New data from the I-SPY 2 trial highlights residual cancer burden as a prognostic indicator for long-term outcomes in patients pre-selected using MammaPrint NBRST trial reports three-year patient outcomes showing that the use of MammaPrint Read More
Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia
Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for early breast cancer IRVINE, CA AND AMSTERDAM, NETHERLANDS – 24 Read More
